TrialNature medicine2024

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Xavier Leleu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.